IRC
VYNE icon

Investors Research Corp’s VYNE Therapeutics VYNE Stock Holding History

Investors Research Corp’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-8
Closed -$23 – 1159
2022
Q4 		$23 Hold
8
– – ﹤0.01% 1134
2022
Q3 		$0 Hold
8
– – ﹤0.01% 1139
2022
Q2 		$0 Hold
8
– – ﹤0.01% 1155
2022
Q1 		$0 Hold
8
– – ﹤0.01% 1101
2021
Q4 		$0 Hold
8
– – ﹤0.01% 1047
2021
Q3 		$0 Buy
8
+5
+167% +$194 ﹤0.01% 1037
2021
Q2 		$0 Hold
3
– – ﹤0.01% 1019
2021
Q1 		$0 Hold
3
– – ﹤0.01% 1082
2020
Q4 		$0 Hold
3
– – ﹤0.01% 1110
2020
Q3 		$0 Buy
+3
New +$350 ﹤0.01% 1134

Other funds holding VYNE

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Investors Research Corp's VYNE Position: Q1 2023 in Review

Investors Research Corp sold out of VYNE Therapeutics (VYNE) in Q1 2023, closing a stake of 8 shares — an estimated $23 sold.

Investors Research Corp first reported a position in VYNE in Q3 2020 and held it in 10 quarters. The position peaked at $23 in Q4 2022. 23 funds tracked by Wall St. Rank hold VYNE as of Q1 2023.

  • Investors Research Corp reported no remaining VYNE Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Investors Research Corp sold 8 VYNE Therapeutics shares in Q1 2023, an estimated $23.
  • Investors Research Corp first reported a position in VYNE Therapeutics in Q3 2020 and held it in 10 quarters.
  • Investors Research Corp's VYNE Therapeutics position peaked at $23 in Q4 2022.
  • 23 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2023.

Based on Investors Research Corp's 13F filing for Q1 2023, filed 11 May 2023.